Editor’s Note: October 26, 2012

Dear Readers,

What an exciting week in our sector. Our Sentinel this week focuses on a handful of companies with powerful technology.

Our “above the fold” stories this week feature two radio interviews with management of DARA BioSciences and Intellicell Biosciences. Both companies have in the past weeks released some important news…we expect to hear their name quite a bit in the next few months.

NeoChord and CEVEC Pharmaceuticals are very interesting private companies making significant strides. In this week’s issue we survey these company milestones and offer a description of technology — and significant market opportunity that awaits.

Of course we can’t forget about Amarantus, which this week released some very promising data. Pre-clinical data in a rat model of Parkinson’s disease suggests positive behavioural efficacy data of the company’s neuron-protective protein MANF when compared to GDNF.

Don’t forget to register for the 6th Annual OneMedForum, taking place January 7th-9th at the Sir Francis Drake Hotel in San Francisco. We’re excited to report a 300% increase in investor attendance as compared to this time last year, and that number is growing every day.

Enjoy this issue.

The comments are closed.